Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	65892
Country	South Korea

Received	2021-03-17 12:30
Peer-Review Started	2021-03-17 12:35
To Make the First Decision
Return for Revision	2021-04-19 02:39
Revised	2021-04-20 04:45
Second Decision	2021-09-09 03:22
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-09-10 09:23
Articles in Press	2021-09-10 09:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-11-09 08:11
Publish the Manuscript Online	2021-11-12 11:22

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Biochemistry & Molecular Biology
Manuscript Type	Editorial
Article Title	Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype
Manuscript Source	Invited Manuscript
All Author List	Keun-Yeong Jeong and Haejun Lee
ORCID	Author(s) ORCID Number Keun-Yeong Jeong http://orcid.org/0000-0002-4933-3493 Haejun Lee http://orcid.org/0000-0002-6284-2903
Funding Agency and Grant Number
Corresponding Author	Keun-Yeong Jeong, PhD, Executive Vice President, Research Assistant Professor, R&D Center, Metimedi Pharmaceuticals, 263 Central ro, Incheon 22006, South Korea. alvirus@naver.com
Key Words	Pancreatic cancer; BRCAness; Poly (ADP-Ribose) polymerase-1; PARylation; Poly (ADP-Ribose) polymerase-1 inhibitor
Core Tip	The incidence of germline mutations of the breast cancer susceptibility gene (BRCA), defined as BRCAness, that can be targeted for pancreatic cancer is 9%-17%. Mutations in BRCAs are responsible for causing genetic instability and worsening the prognosis. Therefore, inhibition of poly (ADP-Ribose) polymerase-1 has emerged as a promising therapeutic target for BRCAness pancreatic cancer within the framework of an increase in genome instability.
Publish Date	2021-11-12 11:22
Citation	Jeong KY, Lee H. Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype. World J Gastrointest Oncol 2021; 13(11): 1544-1550
URL	https://www.wjgnet.com/1948-5204/full/v13/i11/1544.htm
DOI	https://dx.doi.org/10.4251/wjgo.v13.i11.1544

Full Article (PDF)	WJGO-13-1544.pdf
Full Article (Word)	WJGO-13-1544.docx
Manuscript File	65892_Auto_Edited.docx
Answering Reviewers	65892-Answering reviewers.pdf
Audio Core Tip	65892-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	65892-Conflict-of-interest statement.pdf
Copyright License Agreement	65892-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	65892-Language certificate.pdf
Peer-review Report	65892-Peer-review(s).pdf
Scientific Misconduct Check	65892-Bing-Wang JL-1.jpg
Scientific Misconduct Check	65892-Bing-Wang JJ-2.jpg
Scientific Editor Work List	65892-Scientific editor work list.pdf